Form 4: Mirum Pharmaceuticals Director Patrick J. Heron Reports Stock Purchases

Director Patrick J. Heron reports purchases of Mirum Pharmaceuticals stock through Frazier Life Sciences X, L.P., and indirect ownership through Frazier Life Sciences IX, L.P.

Summary

• Patrick J. Heron, a director of Mirum Pharmaceuticals, reported transactions involving the company's common stock.
• On March 6, 2025, 1,335 shares were purchased at a weighted average price of $43.8928, with prices ranging from $43.42 to $44.25.
• On March 7, 2025, 580 shares were purchased at a weighted average price of $43.2145, with prices ranging from $42.79 to $43.42.
• These purchases were made through Frazier Life Sciences X, L.P., where Heron has indirect beneficial ownership.
• Heron also has indirect beneficial ownership of 3,566,912 shares held by Frazier Life Sciences IX, L.P.
• Following these transactions, Heron's indirect beneficial ownership through Frazier Life Sciences X, L.P. increased to 165,825 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The director's purchase of shares could be interpreted as a positive signal about the company's prospects.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry.

Stakeholder Impact

• The stock purchases by a director could have a minor positive impact on shareholder confidence.

Key Dates